American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th. Washington, DC: American Psychiatric Association, 1994.
2.
AndersonRP, MorrisBAP. Acrocyanosis due to imipramine. Arch Dis Child, 63:204–205. 1988.
3.
BymasterFP, KatnerJS, NelsonDL, Hemrick-LueckeSK, ThrelkeldPG, HeiligensteinJH, MorinSM, GehlertDR, PerryKW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27:699–711. 2002.
4.
ClarkDW, Correa–NunesAM, EdwardsIR. Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome)Eur J Clin Pharmacol, 59:261–262. 2003.
5.
DonnellyC, BangsM, TrzepaczP, JinL, ZhangS, WitteMM, BallSG, SpencerTJ. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry, 48:176–185. 2009.
6.
GoldmanW, SeltzerR, ReumanP. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children. Arthritis Rheum, 58:563–566. 2008.
7.
GootschlingS, MeyerS, ReinhardH, KrennT, GrafN. First report of a vincristine dose-related Raynaud's phenomenon in an adolescent with malignant brain tumor. J Pediatr Hematol Oncol, 26:768–769. 2004.
8.
JaffeIA. Serotonin reuptake inhibitors in Raynaud's phenomenon. Lancet, 345:1378–1995.
9.
JainU, HechtmanL, DeclanQet al.CADDRA, Canadian ADHD Practice Guidelines. Toronto: Canadian ADHD Resource Alliance, 2006.
10.
JiaoX, VelezS, RingstadJ, EymaV, MillerD, BleibergM. Myocardial infarction associated with adderal XR and alcohol use in a young man. J Am Board Fam Med, 22:197–201. 2009.
11.
JohnsonS, IazettaJ, DewarC. Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction. J Rheumatol, 30:2503–2505. 2003.
12.
MichelsonD, AllenAJ, BusnerJ, CasatC, DunnD, KratochvilC, NewcornJ, SalleeFR, SangalRB, SaylorK, WestS, KelseyD, WernickeJ, TrappNJ, HarderD. Once-daily atomoxetine treatment for children and adolescentswith attention deficit hyperactivity disorder: A randomized, placebo controlled study. Am J Psychiatry, 159:1896–901. 2002.
TowheedT, DewarC. A practical approach to Raynaud's syndrome. Medicine N Am, 19:56–60. 1996.
18.
TurgayA. Atomoxetine in the treatment of children, adolescents and adults with ADHD. Therapy, 6:19–38. 2006.
19.
VitielloB. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am, 17:459–474. 2008.
20.
ZhouJ. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future, 29:1235–1244. 2004.
